Real-world evaluation of upfront docetaxel in metastatic castration-sensitive prostate cancer

Table 1 Baseline characteristics of the first 94 patients with metastatic castration-sensitive prostate cancer treated with docetaxel and androgen deprivation therapy between July 2015 and December 2017 in the Southeast Health Care region of Sweden

	Total, n = 94 (%)	CHAARTED, ADT + Docetaxel	STAMPEDE, Standard of care + Docetaxel
Age, yr
Median	68.0	64	65
Range	49-79	36-88	40-81
Prostate-specific antigen (μg/L), at diagnosis
Median	180	50.9	70
Range	2-7367	0.2-8540.1	1-9999
Comorbidities, n (%)	50 (53)
Diabetes mellitus I and II	16 (17)		56 (9)
Hyperlipidemia	23 (24)		208 (35)
Hypertension	38 (40)
Previous malignant disease1	11 (11)
Performance status (ECOG)2, n (%)
0	46 (72)	277 (69.8)
1	15 (23)	114 (28.7)
2	3 (5)	6 (1.5)
T category at diagnosis3, n (%)
T1	6 (6)		0
T2	17 (18)		60 (10)
T3	46 (49)		390 (66)
T4	11 (12)		105 (18)
TX	4 (4)		35 (6)
Not assessed	10 (11)
N category at diagnosis3, n (%)
N0	29 (31)		260 (44)
N1	42 (45)		298 (50)
NX	23 (24)		34 (6)
Metastases3, n (%)
Non-distant metastasis4	19 (20)
Distant metastases	75 (80)		362 (61)
Location, n (%)
Bone metastases	74 (79)		307 (52)
Liver metastases	2 (2)		6 (1)
Lung metastases	12 (13)		13 (2)
Lymph node metastases	54 (57)		102 (17)
Gleason sum score, n (%)
≤ 6	2 (2)	21 (5.3)	≤ 7
7	27 (29)	96 (24.2)	110 (19%)
8-10	60 (64)	241 (60.7)	436 (74%)
Unknown	5 (5)	39 (9.8)	46 (8%)
Histology (WHO 2004), n (%)
Acinar adenocarcinoma	86 (92)
Ductal carcinoma	1 (1)
Mixed type	2 (2)
Unknown	5 (5)
Follow-up, months	20
Median (IQR)	13-28
Status last follow-up, n (%)
Alive, no disease progression	15 (16)
Alive, disease progression	65 (69)
Dead of disease	14 (15)

¹Previous non-prostate cancer: Not specified (n = 6), basal cell carcinoma (n = 1), malignant melanoma (n = 2), pancreatic cancer (n = 1), thyroid cancer (n = 1).

²ECOG: Eastern Cooperative Oncology Group performance status. This information was available for 64 of 94 patients (68%).

³Staging according to TNM classification (8^th edition UICC 2017); clinical staging n = 85, pathological staging n = 7. No information was found for n = 2. X means that a substage was not defined.

⁴Locoregional lymph node metastases are referred to as non-distant metastases. Corresponding data from the CHAARTED and STAMPEDE randomized trials[10,11] are shown for comparison.

ADT: Androgen deprivation therapy; PFS: Progression-free survival.